PPT-Multiple Myeloma: Is it now a curable disease?

Pritesh Patel MD OVErview Disease overview How I approach initial treatment Treatment considerations at relapse 96000 MM patients How many people are affected by myeloma National Cancer Institute Survival Epidemiology and End Results Program SEER Cancer Statistics Review 19752012 Available at . Andrzej . J. . Jakubowiak, MD, PhD. Director, Myeloma Program. Director, Clinical Trials Subcommittee, MMRC. Loyola University, May 16, 2015. What is Multiple Myeloma?. Malignant cells grow mostly in bones and secrete monoclonal antibodies . Our Dana-Farber Experience. Deirdre Foley & Matthew Murphy. Our . Dana-Farber Experience. Dr O Gorman (. MIRT . Mater Institute of Blood Cancer Research and Therapy) and Dr Anderson (Dana Farber Cancer Institute, Boston). Ready for Prime Time?. DANA-FARBER . CANCER INSTITUTE. Nikhil C. Munshi, MD . Professor of Medicine . Harvard Medical School. Boston VA Healthcare System. Director . Basic and Correlative Sciences. Dana-Farber Cancer . Round Cell Tumors. Wendy Blount, DVM. Round Cell Tumors. Lymphoma. Mast Cell Tumor. Plasma Cell Tumor. Extramedullary Plasmacytoma. Multiple myeloma . Histiocytic Disease. Transmissible Venereal Tumor. Paul Moss. Birmingham, UK. Outline. Introduction to immunotherapy. Immunotherapy in the setting of Myeloma . Cellular therapy. Future application. History of Cancer Therapy. Surgery. 1000s of years. Radiotherapy. NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. Study of . clinocopathological. profile and chromosomal abnormalities by FISH in newly diagnosed multiple myeloma. Investigator – Dr. . Sukanya. S K.. Guide: Dr. . Shivani. . Vignesh. .. Co-guide- Dr . Copenhagen. , . June 11. th. . 2016. EU Drug Approval and Reimbursement Policy. No standardized. cost-benefit formula exists across the EU. . The Estonian reimbursement committee (Estonian Health Foundation) initially (2013) . Vi Dao, MD, FRCPC. vdao@cancercare.mb.ca. Presenter Disclosure. Faculty: Vi Dao. Relationships with commercial interests: none. Mitigating Potential Bias. Not Applicable. Learning Objectives. Distinguish MGUS from multiple myeloma. H . Nèji. , H . Abid. , A . Mâalej. , S . Haddar. , R . Akrout. *, . M . Ezzeddine. *, S . Baklouti. *, . Z . Mnif. **, J . Mnif. Imaging department . Habib. . Bourguiba. Hospital, . *Rheumatology department . Miss Georgia Stewart . Sheffield Myeloma Research Team. Department of Oncology and Metabolism. Faculty of Medicine Dentistry and Health . University of Sheffield, UK. Most Viruses have a preferential tropism for tumour cells. present s estimate s of how many people in the UK are living with ‘ treatable but not cur able ’ cancer – cancer that can very rarely be cured i , but can be treated to help manage sympt Plasma cell dyscrasias are diseases characterized by clonal proliferation and accumulation of cells producing monoclonal immunoglobulins. These diseases have not been studied in our region and we don IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione. , MD, PhD. Istituto. . Scientifico. Romagnolo per lo Studio e la . Cura. . dei. . Tumori. IRCCS. Meldola. , Italy. HIGHLIGHTS FROM LYMPHOMA & MYELOMA CONNECT.